# SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES

> **NIH NIH N43** · ANTAGEN PHARMACEUTICALS, INC. · 2020 · $600,000

## Abstract

This contract is part of the NIAID Adjuvant Development program, which supports the preclinical development of novel vaccine adjuvant candidates.  The goal of this contract is to support the further development of the C3d-CTB adjuvant within the context of a vaccine to protect against H. pylori.

## Key facts

- **NIH application ID:** 10281998
- **Project number:** 75N93020C00042-0-9999-1
- **Recipient organization:** ANTAGEN PHARMACEUTICALS, INC.
- **Principal Investigator:** WENDA GAO
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $600,000
- **Award type:** —
- **Project period:** 2020-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10281998

## Citation

> US National Institutes of Health, RePORTER application 10281998, SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES (75N93020C00042-0-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10281998. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*